Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants
Preprint
Abstract
A multiplexed, lentivirus-based pseudovirus neutralisation assay (pVNT) was developed for high-throughput measurement of neutralising antibodies (nAbs) against three distinct SARS-CoV-2 spike variants. Intra-assay variability was minimised by optimising the plate layout and determining an optimal percentage transduction for the pseudovirus inoculum. Comparison of monoclonal antibody EC 50 titres between single and multiplexed pVNT assays showed no significant differences, indicating reliability of the multiplexed assay. Evaluation of convalescent human sera confirmed assay validity, with consistent fold drops in EC 50 for variant pseudoviruses relative to the ancestral strain observed across single and multiplexed assays. This multiplexed pVNT provides a reliable tool for assessing nAb responses against SARS-CoV-2 variants and could be used to accelerate preclinical vaccine assessment in preparation for the next coronavirus pandemic.Keywords
All Related Versions
- Published version: Journal of Virological Methods, 332, 115073.
This publication has 25 references indexed in Scilit:
- Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysisThe Lancet Microbe, 2024
- A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategyVaccine, 2023
- WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific communityThe Lancet Microbe, 2022
- The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitroVirologica Sinica, 2022
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisThe Lancet Microbe, 2021
- Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA DisplayACS Central Science, 2021
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patientsCell, 2021
- Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease OutbreaksStem Cell Reports, 2021
- Practical Guidelines for Collection, Manipulation and Inactivation of SARS‐CoV‐2 and COVID‐19 Clinical SpecimensCurrent Protocols in Cytometry, 2020
- Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale productionThe Journal of Gene Medicine, 2005